Evogene Ltd.
EVGN
$0.76
-$0.02-2.05%
NASDAQ
| 12/31/2025 | 06/30/2025 | 12/31/2024 | 09/30/2024 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 314.00K | 884.00K | 1.54M | 1.74M | 3.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 314.00K | 884.00K | 1.54M | 1.74M | 3.77M |
| Cost of Revenue | 2.28M | 136.00K | 692.00K | 1.04M | 511.00K |
| Gross Profit | -1.97M | 748.00K | 851.00K | 698.00K | 3.26M |
| SG&A Expenses | 1.20M | 1.50M | 1.63M | 3.31M | 2.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -27.00K | -- | -- | -- | -- |
| Total Operating Expenses | 5.28M | 3.96M | 5.01M | 7.66M | 7.95M |
| Operating Income | -4.97M | -3.07M | -3.47M | -5.92M | -4.18M |
| Income Before Tax | -5.34M | -4.68M | 990.00K | -6.75M | -3.86M |
| Income Tax Expenses | 0.00 | 1.00K | 7.00K | 1.00K | -5.00K |
| Earnings from Continuing Operations | -5.34M | -4.68M | 983.00K | -6.75M | -3.86M |
| Earnings from Discontinued Operations | -16.00K | -- | -988.00K | -1.47M | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 45.00K | 219.00K | 432.00K | 589.00K | -126.00K |
| Net Income | -5.31M | -4.46M | 427.00K | -7.63M | -3.98M |
| EBIT | -4.97M | -3.07M | -3.47M | -5.92M | -4.18M |
| EBITDA | -4.70M | -2.78M | -3.82M | -5.71M | -3.52M |
| EPS Basic | -0.61 | -0.62 | 0.28 | -1.31 | -0.81 |
| Normalized Basic EPS | -0.36 | -0.27 | -- | -- | -0.52 |
| EPS Diluted | -0.61 | -0.62 | 0.28 | -1.31 | -0.81 |
| Normalized Diluted EPS | -0.36 | -0.27 | -- | -- | -0.52 |
| Average Basic Shares Outstanding | 8.72M | 7.23M | 5.70M | 5.81M | 4.89M |
| Average Diluted Shares Outstanding | 8.72M | 7.23M | 5.70M | 5.81M | 4.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |